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Objectives This study investigated the role of adrenergic receptor genetics on transplant-free survival in heart failure (HF).
Background Discordant results exist for genetic associations between adrenergic receptor alleles and end points of -blocker
response in HF patients.
Methods We identified 637 patients enrolled in 2 U.S. cardiovascular genetic registries with HF and left ventricular sys-
tolic dysfunction who were discharged on -blocker, angiotensin-converting enzyme inhibitor (ACEI) or angioten-
sin II receptor blocker (ARB), and diuretic medications. End points were determined through the national Social
Security Death Master File and transplant records. We genotyped 5 polymorphisms in 3 genes: ADRB1 (S49G,
R389G), ADRB2 (G16R, Q27E), and ADRA2C (Del322-325) using 5= nuclease assays and performed a multivari-
able clinical-genetic analysis.
Results A total of 190 events (29.8%) occurred over a median follow-up of 1,070 days. Multivariable analysis showed a
significant effect of 4 clinical factors on survival: age (p  0.006), gender (p  0.005), ejection fraction (p 
0.0002), and hemoglobin (p  0.00010). There was no significant effect of the polymorphisms or haplotypes
analyzed on survival.
Conclusions Genotypes and haplotypes of ADRB1, ADRB2, and ADRA2C did not significantly affect survival in metoprolol-
treated or carvedilol-treated HF patients in this study. These results complement the findings of 2 similarly de-
signed previous studies, but do not replicate an association of ADRB2 haplotypes and survival. All 3 studies dif-
fer from a survival benefit reported for bucindolol-treated homozygous ADRB1 R389 individuals. This may be
attributable to a drug-specific interaction between genotype and outcome with bucindolol that does not seem to
occur with metoprolol or carvedilol. (J Am Coll Cardiol 2008;52:644–51) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.022n
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neart failure (HF) affects 5 million Americans and repre-
ents a major health care challenge, with 500,000 new cases
nd 250,000 deaths each year (1). Heart failure may arise
rom ischemic or nonischemic injury, and the natural history
an differ widely among individuals, even those with similar
ardiomyopathic states (2,3). Identifying responders and
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ork was funded by CardioDx, Inc.p
Manuscript received February 7, 2008; revised manuscript received April 29, 2008,
ccepted May 5, 2008.onresponders to HF therapies could lead to improved
uality of care and better allocation of medical resources
4,5).
See page 652
Central to the development, progression, and mode of
reatment in HF is the adrenergic system, which is modu-
ated through a family of pre-synaptic and post-synaptic -
nd -adrenergic receptors (ARs) (6,7). In particular, pre-
ynaptic 2C-ARs (responsible for norepinephrine release)
nd cardiomyocyte 1- and 2-AR (the targets for norepi-
ephrine and -blockers) form a “circuit” that may initially
romote maintenance of cardiac output, but ultimately act
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August 19, 2008:644–51 Adrenergic Receptor Genetics in HFo accelerate progression of failure (8). These phenomena
ave been extensively studied and are shown to play an
mportant role in the pathophysiology and progression of
F. As a result, treatment of HF patients with -blockers
as become a standard of care, which in the U.S. consists
rimarily of the use of 2 drugs, metoprolol succinate and
arvedilol (9,10). Both metoprolol and carvedilol block
1-AR as well as display other unique and drug-specific
roperties. Given the existence of genetic polymorphisms in
he adrenergic receptor genes encoding 2C-AR, 1-AR,
nd 2-AR (ADRA2C, ADRB1, ADRB2, respectively), the
ritical question has been raised as to whether genetic
ariations explain differences in individual -blocker thera-
eutic response (11,12).
Over the past 10 years, several studies have shown that
ingle-nucleotide polymorphisms (SNPs) in the ADRB1,
DRB2, and ADRA2C genes influence receptor function
n vitro and in vivo (6,7). For example, the arginine
esidue at position 389 of the 1-AR gene (ADRB1
389) alters the receptor-Gs interaction and acts as a
ain-of-function polymorphism (13). This interesting
esult subsequently triggered a series of investigations
nto ADRB1 and other SNPs in HF patients to assess the
otential relationship between patient genotype and re-
ponse to therapy. Several of these studies report signif-
cantly different responses based on genotype for end
oints such as exercise capacity, initial tolerability during
-blocker titration, changes in left ventricular ejection
raction (LVEF), and changes in left ventricular (LV)
emodeling in response to -blocker therapy (14 –19). To
ate, not all of the reported associations have been
ndependently replicated, making it difficult to draw
efinitive conclusions for clinical use (11,12,20). For the
ore clinically relevant outcome of survival in HF
atients, the results are also mixed, although 2 recent
eports are notable. One study shows unfavorable survival
utcomes for clinically treated HF patients with a ho-
ozygous haplotype in the ADRB2 gene, 16/27 RQ (21).
nother study from the BEST (-blocker Evaluation of
urvival Trial) shows significantly reduced mortality in
ucindolol- versus placebo-treated HF patients who are
DRB1 R389 homozygotes (16). To test the hypothesis
hat adrenergic receptor genotypes affect the critical end
oint of survival in -blocker–treated HF patients, we
erformed a large, dual-center study with comprehensive
enotyping and analysis of SNPs in the ADRB1, ADRB2,
nd ADRA2C genes and haplotypes in ADRB1 and
DRB2.
ethods
tudy population. The starting population for this study
as identified within cardiac catheterization laboratory-
ased genetic registries at the Duke University Medical
enter, CATHGEN (22), and the Utah-based Registry ofhe Intermountain Heart Collaborative Study (23). Registry tizes at the time of database
earch were 5,172 for CATH-
EN and 14,085 for Registry of
he Intermountain Heart Collab-
rative Study. Blood samples for
enetic storage were obtained at
he time of cardiac catheteriza-
ion. Clinical data were obtained
hrough a combination of regis-
ry database queries as well as
anual chart abstraction of med-
cation records and defined clin-
cal data fields.
These studies were conducted
n compliance with human stud-
es committees at Duke Univer-
ity and Intermountain Health-
are. Written informed consent
as obtained from the study sub-
ects at each institution for par-
icipation in their cardiovascular
enetics registries. The institu-
ional committee on human re-
earch at Duke University and Intermountain Healthcare
lso approved the current study protocol as performed.
We initially searched the 2 registry databases for patients
ith clinical diagnosis of HF and/or LV systolic dysfunction
ith ejection fraction (EF) 40% at the time of catheter-
zation. Of the 1,405 patients identified, we subsequently
xcluded 768 subjects for 1 or more of the following reasons
ased on pre-defined study criteria: patient not discharged
n standard HF medications including -blocker (metopro-
ol succinate or carvedilol), angiotensin-converting enzyme
nhibitor (ACEI) or angiotensin II receptor blocker (ARB),
nd/or loop diuretic; undocumented EF or EF 40%
diastolic HF); fewer than 30 days elapsed between most
ecent myocardial infarction and cardiac catheterization;
erum creatinine 2.0 mg/dl; valve or congenital heart
isease as primary cause of LV dysfunction; severe, life-
hreatening noncardiac comorbidities; or inadequate de-
xyribonucleic acid (DNA) sample for genotyping. For
atients with undocumented New York Heart Association
NYHA) functional class, we required treatment with a loop
iuretic as evidence of clinically symptomatic HF (shortness
f breath, fluid accumulation). Baseline LVEF 40% was
equired for inclusion, which for the majority of patients was
etermined by ventriculogram on the date of catheterization
r by echocardiogram within 6 months of catheterization.
or some patients, the method for determining EF was not
ocumented in the chart. Ischemic or nonischemic HF
tiology was assigned using results of coronary angiography
nd information in the medical record. Patients were
lassified as ischemic HF if they showed 70% diameter
tenosis in at least 1 major coronary artery, or had a prior
istory of myocardial infarction or coronary revasculariza-
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AR  adrenergic receptor
ARB  angiotensin II
receptor blocker
CI  confidence interval
EF  ejection fraction
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
SNP  single-nucleotide
polymorphismion. Within the nonischemic population, we also identified
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oints at each institution for minimal coronary artery
tenosis (25% stenosis, Duke; and 10% stenosis, Regis-
ry of the Intermountain Heart Collaborative Study).
efinition of study period and end point determination.
he period of study for all patients was indexed from the
ate of cardiac catheterization (T0; range January 17, 1998,
o June 26, 2006) through the date of end point determi-
ation (March 1, 2007) or until date of death or heart
ransplantation, whichever came first. End point determi-
ation was made through search of the Social Security
eath Master File (24) and search of cardiac transplant
ecords at each institution. Outcome data were kept at each
nstitution and separate from genotyping and clinical data
ntil the time of statistical analysis.
enetic analysis (genotyping). Genomic DNA was iso-
ated from whole blood using a commercially available kit
PureGene, Gentra Systems, Minneapolis, Minnesota) and
iluted to a concentration of 4 ng/l; 12 ng was used in each
ssay. The genotypes were determined by polymerase chain
eaction using 5= nuclease genotyping assays (Applied Bio-
ystems, Foster City, California). For ADRB1 S49 and
389, Assays on Demand were used (Assay numbers
_8898508_10 and C_8898494_10). For ADRB2 G16
nd Q27, Assays-by-Design were created using the primer
nd probe sequences listed in the Online Appendix. The
mino acid position 322 insertion/deletion variant in the
DRA2C gene was less amenable to the genotyping plat-
orm, so we utilized a surrogate marker, which is an SNP
hat is in high linkage disequilibrium (r2  0.924) to the
eletion as described by Small et al. (25) (SNP “H”). Primer
nd probe sequences for this assay are also shown in the
nline Appendix. For purposes of presentation, these
esults are shown as the insertion/deletion polymorphism at
osition 322 because this variation has been shown to affect
eceptor function.
tatistical methods. CLINICAL ANALYSIS. To assess the
ssociation of clinical characteristics with study end
oints, a series of univariate proportional hazards regres-
ion models were fit, 1 model for each of 12 pre-defined
linical factors. We prospectively defined a significance
evel of p  0.10 for inclusion of clinical factors in the
ultivariable analysis.
LINICAL-GENETIC ANALYSIS. Hardy-Weinberg equilib-
ium was assessed by the chi-square test. When possible,
issing SNP calls were imputed via the expectation maxi-
ization algorithm (26). To assess the association of SNPs
ith study end points, each SNP was analyzed in a
roportional hazards regression model that included the
ignificant factors from the clinical multivariable analysis. In
ddition, haplotypes were determined for ADRB1 and
DRB2 using 2 coding SNPs in each gene. In our popula-
ion, there were 3 ADRB1 haplotypes (S49/R389, S49/
389, G49/R389) and 3 ADRB2 haplotypes (R16Q27,
16E27, G16Q27) present. These 6 haplotypes were ana- fyzed individually in the same manner as the individual
NPs (clinical-adjusted proportional hazards regression
odel).
In the primary analysis, SNPs or haplotypes were ana-
yzed in the models with a 0/1/2 code reflecting the number
f copies of the minor allele for a particular SNP. The
xpectation maximization algorithm was used to estimate
he number of copies from 0 to 2 of each haplotype for each
ndividual. Secondary analyses were also performed where
he heterozygotes were combined either with the 0 copy
01/2; wild type or 1 copy of minor allele vs. 2 copies of
inor allele) or with the 2 copy group (0/12; wild type vs.
t least 1 copy of minor allele). In addition, the 5 SNPs were
ssessed in a combined model to evaluate whether there was
n aggregate genetic effect. All analysis was performed using
he R statistical package (27).
TUDY POWER. Given the cohort size, event rate, and range
f gene allele frequencies analyzed, this study was 80%
owered to detect between a 9% difference in survival (for
ost prevalent SNP) and 13% difference in survival (for
east prevalent SNP).
esults
linical analysis. The study cohort consists of 637 subjects
CATHGEN n  344, Registry of the Intermountain
eart Collaborative Study n  293), whose complete
aseline clinical characteristics are shown in Table 1. All
37 patients had LV systolic dysfunction and were dis-
harged on a combination of -blocker (metoprolol or
arvedilol), ACEI or ARB, and loop diuretic; 69% had
schemic heart disease and 22% had implanted defibrillator
evices.
There were 190 events (29.8%; 150 deaths, 40 trans-
lants) over a median follow-up of 1,070 days (2.9 years;
ange 5 to 3,188 days). Minimum follow-up for a subject
ithout an event was 248 days. Clinical factors selected for
nivariable end point analysis included those previously
hown to be clinical predictors of survival in the Seattle HF
odel (age, gender, LVEF, NYHA functional class, HF
tiology, systolic blood pressure, hemoglobin, and statin
se) (28). In addition to these factors, we also studied the
ffect of race, history of diabetes, -blocker medication, and
resence of an implantable cardioverter-defibrillator (ICD)
evice on survival in our cohort. Eight clinical factors met
he pre-defined univariable significance of p  0.1 for
nclusion in the multivariable model (Table 2). Of these, 4
etained significance (p  0.05) in the multivariable analy-
is: age (p  0.006), male gender (p  0.005), low EF (p 
.0002), and low hemoglobin (p  0.0001). Systolic blood
ressure showed a trend toward significance (Table 2).
linical-genetic analysis—single SNPs. Genotypes were
enerated for 637 patients with a call rate for all SNPs
cross the entire cohort of 98.3%. All alleles were in
ardy-Weinberg equilibrium, and minor allele frequenciesor our cohort were in agreement with other major studies:
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August 19, 2008:644–51 Adrenergic Receptor Genetics in HFDRB1 G49 15%, G389 29.5%, and ADRB2 R16 40%,
27 36.5% (12,21,29,30). Allele frequencies for the deletion
olymorphism in ADRA2C differed by race, but were in
ardy-Weinberg equilibrium for each race when consid-
red separately.
We found no significant effect on transplant-free survival
or the primary analysis of 5 SNPs in the ADRB1, ADRB2,
r ADRA2C genes (Fig. 1, Table 3). A death-only analysis
lso did not yield significant results. Considering the po-
ential influence of ICDs on outcome, we performed sec-
ndary SNP analyses in the device (n  141) and no-device
n  496) subgroups, but did not identify a significant
ffect. The number of patients with biventricular ICDs was
oo small (n  39) to provide any further meaningful
nalysis. Other independent secondary subgroup analyses of
he “clean coronary” nonischemic patients and NYHA
unctional class III/IV patients were also noninformative.
A weak univariable trend toward better survival in black
atients was observed, as an additive function of the number
f alleles in the ADRA2C deletion polymorphism (hazard
atio [HR]: 0.55, 95% confidence interval [CI]: 0.28 to
.11, p 0.094 for black patients only; compared with HR:
.95, 95% CI: 0.57 to 1.59, p  0.85 for Caucasians only)
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Clinical Factor
Combined Cohort
(n  637)
Age (yrs) 61.7 13.34
Men 471 (74)
Caucasian 481 (75)
Metoprolol 361 (56.7)
Carvedilol 276 (43.3)
EF (%) 27 8.63
EF determined by ventriculogram 377 (59.2)
EF determined by echocardiogram 179 (28.1)
EF method not documented 81 (12.7)
NYHA functional class
I 11 (1.7)
II 117 (18.4)
III 218 (34.2)
IV 112 (17.6)
Unknown 179 (28.1)
SBP (mm Hg) 134 23
Hemoglobin (g/dl) 14 1.88
Statin use 372 (58.4)
History of diabetes 189 (29.7)
History of hypertension 403 (63)
History of myocardial infarction 236 (37)
Ischemic 440 (69.1)
Nonischemic 197 (30.9)
Nonischemic “clean coronary” subgroup 138 (22)
Biventricular pacemaker defibrillator 39 (6)
Implanted defibrillator; includes patients with
biventricular pacemaker defibrillator
141 (22.1)
alues are presented as n (%) or mean  SD.
EF  ejection fraction; NYHA  New York Heart Association; SBP  systolic blood pressure.Figs. 1E and 1F). There were no other trends for Cauca- aian or black patients when performing secondary analyses
ithin each race.
linical-genetic analysis—haplotypes. We analyzed 3
aplotypes for both ADRB1 (S49/R389, S49/G389, G49/
389) and ADRB2 (R16Q27, G16E27, G16Q27) that
ere inferred using the expectation maximization algorithm
nd a 0/1/2 coding to reflect the number of copies of each
articular haplotype. We found no genetic association in
ny of the primary haplotype analyses or in any of the
econdary subgroup analyses described above.
iscussion
ased on the potential of adrenergic receptor genetics to
nfluence survival in HF patients, we chose to examine a
ohort of clinically treated HF patients who had been
rescribed metoprolol or carvedilol. To extend published
tudies in this area by White et al. (30), de Groote et al.
29), and Shin et al. (21), our cohort included a larger
umber of patients from 2 centers and a greater proportion
f nonwhite patients, and we comprehensively examined
NPs and haplotypes in 3 major adrenergic receptor genes
Tables 4 and 5). The cohort was enrolled from patients
ho underwent cardiac catheterization between January 1,
998, and June 30, 2006, which represents an interval of
tandardized HF pharmacotherapy. Subjects were included
ho met the criteria of LV systolic dysfunction (EF40%),
ad a clinical diagnosis of HF, were more than 30 days from
revious myocardial infarction at the time of catheteriza-
linical Analysis
Table 2 Clinical Analysis
Variable HR 95% CI p Value
Univariable analysis
Age at baseline 1.020 (1.008–1.032) 0.0007*
Male gender 1.391 (0.981–1.972) 0.064*
Baseline EF 0.975 (0.959–0.991) 0.003*
Hemoglobin 0.882 (0.818–0.950) 0.001*
Systolic blood pressure 0.992 (0.985–0.999) 0.026*
Ischemic etiology 1.700 (1.210–2.380) 0.0021*
ICD 1.600 (1.150–2.230) 0.005*
Black race 0.508 (0.323–0.801) 0.004*
NYHA functional class 1.204 (0.955–1.519) 0.12
Statins 0.903 (0.679–1.202) 0.48
Diabetes 1.069 (0.788–1.450) 0.67
-blocker type 0.828 (0.622–1.102) 0.19
Multivariable clinical model
Age at baseline 1.017 (1.004–1.031) 0.01300†
Male gender 1.711 (1.126–2.600) 0.01200†
Baseline EF 0.963 (0.945–0.982) 0.00011†
Hemoglobin 0.852 (0.783–0.927) 0.00021†
Systolic blood pressure 0.993 (0.985–1.000) 0.05800
Ischemic etiology 1.318 (0.894–1.943) 0.16000
ICD 1.390 (0.970–1.990) 0.074
Black race 0.673 (0.406–1.116) 0.12000
Factors with p  0.10 in univariable analysis were included in multivariable model. †Significant
actors (p  0.05) for transplant-free survival.
CI  confidence interval; HR  hazard ratio; ICD  implantable cardioverter-defibrillator; other
bbreviations as in Table 1.
t
i
P
t
h
i
648 Sehnert et al. JACC Vol. 52, No. 8, 2008
Adrenergic Receptor Genetics in HF August 19, 2008:644–51ion, and were discharged on standard HF medications
ncluding -blocker, ACEI or ARB, and/or loop diuretic.
atients were followed up to the end point of death or
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August 19, 2008:644–51 Adrenergic Receptor Genetics in HFeiterates the importance of recognizing anemia in this
ondition (28,31). At the same time, we found no signifi-
ant effect of the polymorphisms or haplotypes we analyzed
n ADRB1, ADRB2, or ADRA2C on transplant-free sur-
ival. Despite showing almost identical haplotype frequen-
ies, we did not replicate either an adverse effect on
ransplant-free survival of 2 copies of the ADRB2 RQ
aplotypes previously reported by Shin et al. (21), or an
dverse effect of 2 copies of the ADRB2 GQ haplotype as
reviously reported by de Groote et al. (30) (Table 4). This
ay be in part attributable to smaller numbers of patients in
hose studies or to a population effect. In terms of the other
NPs analyzed, the published datasets show no effect of the
DRB1 R389G SNP in HF survival in now over 1,500
-blocker–treated subjects (637 from this study) (Table 6).
urthermore, no effect of SNPs in ADRB1 (S49G), ADRB2
G16R and Q27E), or haplotypes in ADRB1 have been
ound in over 1,200 -blocker–treated subjects. Taken
ogether, these results lead us to conclude that there is no
ignificant association between adrenergic receptor geno-
linical-Genetic Analysis
Table 3 Clinical-Genetic Analysis
HR 95% CI p Value
SNP
ADRB1 G49 1.120 (0.822–1.525) 0.470
ADRB1 G389 0.980 (0.773–1.242) 0.870
ADRB2 R16 1.040 (0.835–1.294) 0.730
ADRB2 E27 0.888 (0.710–1.110) 0.300
ADRA2C del Caucasian 0.951 (0.570–1.586) 0.850
ADRA2C del African
American
0.553 (0.276–1.107) 0.094
Haplotype
ADRB1 GR 1.120 (0.822–1.525) 0.470
ADRB1 SR 0.962 (0.771–1.201) 0.730
ADRB1 SG 0.980 (0.773–1.242) 0.870
ADRB2 RQ 1.040 (0.835–1.294) 0.730
ADRB2 GQ 1.115 (0.863–1.440) 0.410
ADRB2 GE 0.888 (0.710–1.110) 0.300
bbreviations as in Table 2.
aplotype Frequencies and Copy Numbers for ADRB1 and ADRB2
Table 4 Haplotype Frequencies and Copy Numbers for ADRB1 a
ADRB1 SR ADRB1 SG
0 copies
Current cohort 122 (19%) 320 (50%)
Shin et al. (21) 52 (23%) 93 (41%)
de Groote et al. (29) — —
1 copy
Current cohort 316 (50%) 259 (41%)
Shin et al. (21) 112 (49%) 108 (48%)
de Groote et al. (29) — —
2 copies
Current cohort 197 (31%) 56 (9%)
Shin et al. (21) 63 (28%) 26 (11%)
de Groote et al. (29) — —Associated with unfavorable outcome by Shin et al. (21). †Associated with unfavorable outcome by deype and survival in the clinical setting of HF treatment with
etoprolol and carvedilol.
For the ADRB1 R389G polymorphism, a recent BEST
NA substudy of 1,040 patients (515 treated) has shown a
ignificant pharmacogenetic association in HF survival be-
ween bucindolol-treated R389 homozygotes and placebo
HR: 0.62, 95% CI: 0.40 to 0.96, p  0.03) (16). Bucin-
olol has a specific pharmacologic profile (reviewed by
iggett et al. [16]), which may be the basis for the unique
ssociation of ADRB1 R389R with treatment response in
eart failure. Unlike metoprolol (but like carvedilol), bucin-
olol has affinity for both the 1- and 2-AR subtypes.
lthough initial studies in nonhuman tissue suggested a
artial agonist effect in the heart, subsequent studies in
umans showed no such effect. In ex vivo human trabeculae
tudies from failing explanted hearts, bucindolol showed
nverse agonist properties (i.e., it decreased contractility),
ut only in ADRB1 R389 homozygotes (16). In contrast,
arvedilol had no such effect (16), nor does metoprolol (S.B.
iggett, unpublished data, June 2007). In addition, bucin-
olol evokes a distinct sympatholysis effect (by an unclear
echanism), lowering plasma norepinephrine levels to a
uch greater extent than metoprolol or carvedilol. Taken
ogether, these characteristics of bucindolol may account for
he pharmacogenetic effect of ADRB1-389 when this drug
s used for heart failure treatment. Another possibility is that
BEST-specific population effect exists; however, this can
nly be addressed through independent replication.
tudy limitations. Lacking a placebo-controlled, single
-blocker trial such as the genetic substudies performed in
EST and MERIT-HF (Metoprolol CR/XL Randomized
ntervention Trial in Congestive Heart Failure), we used
ntent to treat with -blockers at discharge as an inclusion
riterion. To address this limitation, we evaluated medica-
ion records for 310 patients at a second time point at least
0 days from the index date, and found that 94% remained
n -blocker therapy. Sufficient data did not exist to
erform a genotype–-blocker dosage effect in this study.
e identified HF patients in cardiac catheterization
DRB2
B1 GR ADRB2 GQ ADRB2 GE ADRB2 RQ
(73%) 376 (59%) 263 (41%) 239 (38%)
(77%) 135 (59%) 98 (44%) 85 (37%)
— — — —
(25%) 229 (36%) 277 (44%) 290 (46%)
(23%) 76 (33%) 99 (43%) 104 (46%)
— — — —
(2%) 31 (5%) 96 (15%) 107 (17%)
(0%) 16 (7%) 30 (13%) 38* (17%)
— 44† (10%) 82 (18%) 61 (14%)nd A
ADR
462
174
161
53
12
0Groote et al. (29).
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lthough the baseline clinical characteristics are remarkably
imilar to those of other studies (Table 5), we cannot
xclude other potential biases of this approach. The inher-
nt difficulty in defining the onset of HF in an individual
atient remains an overall limitation for a time-to-event
nalysis. For consistency across patients and sites in this
tudy, we defined the date of catheterization as the index
ime. Finally, although we examined the most common
oding SNPs in ADRA2C, ADRB1, and ADRB2, we cannot
xclude that other SNPs in noncoding regions or more
linical Factors in Heart Failure Survival Studies Studying Adrenerg
Table 5 Clinical Factors in Heart Failure Survival Studies Study
Clinical Factor Current Cohort Shin et al. (21)
Study number 637 227
Primary end point Death  transplant Death  transplant
Age (yrs) 61.7 13.34 54.9 13
Men 471 (74) 156 (68)
Caucasian 481 (75) 188 (82)
Metoprolol 361 (56.7) NA
Carvedilol 276 (43.3) NA
Bisoprolol 0 0
-blocker, unspecified 0 183 (81%)
EF (%) 27 8.63 25 12
NYHA functional class — —
I 11 (1.7) 14 (7)
II 117 (18.4) 85 (27)
III 218 (34.2) 98 (43)
IV 112 (17.6) 30 (13)
Unknown 179 (28.1) —
History of diabetes 189 (29.7) 56 (25)
Ischemic 440 (69.1) 105 (46)
History of MI 236 (37) 101 (45)
History of HTN 403 (63) 120 (53)
alues are presented as n (%) or mean  SD.
HTN  hypertension; MI  myocardial infarction; NA  not available; other abbreviations as in
esults of Genetic Studies in -blocker–Treated Heart Failure Patie
Table 6 Results of Genetic Studies in -blocker–Treated Heart
ADRB1 S49G ADRB1 R389G ADRB2 G1
Current cohort p 0.47 p 0.87 p 0.73
Shin et al. (21) NS NS NS
de Groote et al. (29) NS NS NS
White et al. (30),
MERIT-HF
— p 0.74 —
Liggett et al. (16),
BEST
— R389R bucindolol-treated
patients had better
survival compared
with R389R placebo-
treated patients HR:
0.62, 95% CI: 0.40 to
—S  not statistically significant; other abbreviations as in Table 2.xtensive haplotypes not tested in this study may be asso-
iated with -blocker response in heart failure (25,32,33).
onclusions
e conclude that the findings of the current study and
he weight of published evidence show no effect of the
elected 1-, 2-, and 2C-AR polymorphisms or limited
aplotypes on survival in HF patients treated with
etoprolol or carvedilol. The complexities of HF and
aried responses to HF polypharmacy (some of which
ceptor Genetics
drenergic Receptor Genetics
de Groote et al. (29) White et al. (30)
444 600 (307 treated)
Cardiac death or urgent transplant All-cause mortality or hospitalization
56.6 11.9 66.2 8.7
364 (82) 507 (84.5)
444 (100) 584 (97.3)
0 307 (51.1)
NA 0
NA 0
444 (100) 0
32 12 30 10
— —
— 0
— 267 (44.5)
III IV (25) 312 (52)
— 21 (3.5)
— —
134 (30) 95 (15.9)
191 (43) 424 (70.6)
— 308 (51.3)
173 (39) 200 (33.3)
.
ith Survival End Points
re Patients With Survival End Points
ADRB2 Q27E
ADRA2C
Del322-325
ADRB1 49/389
SR, SG, GR
ADRB2 16/27
RQ, GE, GQ
p 0.30 p 0.85
Caucasian,
p 0.094 African
American
NS NS
NS NS NS 2 copies RQ HR:
1.91, 95% CI:
1.09 to 3.36
(p 0.024)
NS — NS 2 copies GQ
p 0.01
(univariate)
— — — —
— Unpublished — —ic Re
ing Ants W
Failu
6R
0.96 (p 0.03)
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APPENDIX
or primer and probe sequences, please see the online version of this
rticle.
